Report Content
Chapter 1 Methodology& Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast calculation
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of parasitic infections
3.2.1.2 Increasing government initiatives and funding
3.2.1.3 Increasing global travel and migration
3.2.2 Industry pitfalls & challenges
3.2.2.1 Increasing drug resistance
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Anthelmintics
5.3 Antiprotozoal
5.4 Ectoparasiticides
5.5 Other drug types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Injectable
6.3 Oral
6.4 Topical
Chapter 7 Market Estimates and Forecast, By End-user, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacy
7.3 Retail pharmacy
7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Bayer AG
9.2 Cipla Inc.
9.3 Dr. Reddy’s Laboratories Ltd,
9.4 GlaxoSmithKline plc
9.5 Glenmark Pharmaceuticals Ltd
9.6 Ipca Laboratories Ltd.
9.7 Mankind Pharma
9.8 Merck KGaA
9.9 Novartis AG
9.10 Sanofi
9.11 Zydus Group
